Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 19, 2022 (Event Date: August 23, 2022)
Context: The Company, an emerging growth company incorporated in British Columbia, filed this report to announce a material modification to the rights of security holders regarding a reverse stock split intended to regain compliance with Nasdaq listing requirements.
Key Financial Metrics
This filing is a current report regarding a corporate action and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for these metrics.
Material Changes
- Reverse Stock Split: The Board of Directors approved a 1-for-25 reverse stock split of all issued and outstanding common shares.
- Share Count Reduction: Outstanding common shares will be reduced from 18,014,937 to approximately 720,597 on a non-diluted basis.
- Security Adjustments: Exercise prices and share counts for outstanding stock options, warrants, and convertible securities will be proportionately adjusted.
- Fractional Shares: Fractional shares less than half will be cancelled; those at least half will be rounded up to one whole share. No fractional shares will be issued.
- Trading Details: Shares will be assigned a new CUSIP (457637601) and are expected to begin trading on a split-adjusted basis on September 7, 2022.
Guidance, Outlook, and Risks
Management Commentary: The primary objective of the consolidation is to regain compliance with all of Nasdaq's continued listing requirements. The Company stated that immediately after the consolidation, each shareholder will hold the same percentage of common shares outstanding as held immediately prior.
Risks and Contingencies: The filing notes that the information is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability exposure for the forward-looking statements contained in the press release.
Investor Verification Checklist
- Verify the effective date of the reverse stock split (expected September 7, 2022).
- Confirm the new CUSIP number (457637601) for trading purposes.
- Review the treatment of fractional shares (rounding rules) for individual holdings.
- Check for subsequent filings regarding the adjustment of outstanding options and warrants.
- Monitor Nasdaq compliance status post-implementation of the split.